JRC Publications Repository

JRC Publications Repository >

Browsing by Author BRUCHERTSEIFER Frank

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:   
Sort by: In order: Results/Page Authors/Record:
Showing results 68 to 87 of 87
Publication YearTitleAuthor(s), Editor(s), Other Contributor(s)Publication Type
2014Retention studies of recoiling daughter nuclides of 225Ac in polymer vesiclesWANG G.; DE KRUIJFF R. M.; ROL A; THIJSSEN L.; MENDES E; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; STUART M.c.a.; WOLTERBEEK H.th.; DENKOVA A.g.Articles in Journals
2009Spectroscopic Study of the Interaction of U(VI) with Transferrin and Albumin for Speciation of U(VI) under Blood Serum ConditionsMONTAVON Gilles; APOSTOLIDIS Christos; BRUCHERTSEIFER Frank; REPINC Urska; MORGENSTERN AlfredArticles in Journals
2013Substance P - nanozeolite labeled with 224Ra and 225Ra - new potential radiobioconjugate for internal alpha therapyLESZCZUK Edyta; PIOTROWSKA A; KOŹMIŃSKI P; BILEWICZ Aleksander; MORGENSTERN Alfred; BRUCHERTSEIFER FrankContributions to Conferences
2012Synthesis and in vitro evaluation of 225Ac-DOTA-SubstanceP for targeted alpha therapy of glioblastoma multiformeMAJKOWSKA AGNIESZKA; BRUCHERTSEIFER Frank; WEIS Mirjam; BONELLI Milton; LAURENZA M; APOSTOLIDIS Christos; MORGENSTERN AlfredContributions to Conferences
2013Synthesis of 213Bi-DOTATOC for peptide receptor a-therapy of GEP-NET patients refractory to β-therapyBRUCHERTSEIFER Frank; MORGENSTERN Alfred; APOSTOLIDIS Christos; GIESEL Frederik; MIER Walter; HABERKORN Uwe; KRATOCHWIL ClemensContributions to Conferences
2012Synthesis of 213Bi-DOTATOC for peptide receptor alpha-therapy of GEP-NET patients refractory to beta therapyMORGENSTERN Alfred; BRUCHERTSEIFER Frank; APOSTOLIDIS Christos; GIESEL Frederik; MIER Walter; HABERKORN Uwe; KRATOCHWIL ClemensContributions to Conferences
2013Targeted alpha therapy of glioblastoma multiforme with 213Bi-substance PMORGENSTERN Alfred; KROLICKI Leszek; KUNIKOWSKA Jolanta; KOCIARA Henryk; KROLICKI B; JAKUCINSKI M; MIKOŁAJCZAK Renata; PAWLAK Dariusz; APOSTOLIDIS Christos; BRUCHERTSEIFER FrankContributions to Conferences
2013Targeted alpha therapy of glioblastoma multiforme: initial clinical experience with 213Bi-substance PMORGENSTERN Alfred; KROLICKI Leszek; KUNIKOWSKA Jolanta; KOZIARA H; KROLICKI B; JAKUCINSKI M; MIKOŁAJCZAK Renata; PAWLAK Dariusz; APOSTOLIDIS Christos; BRUCHERTSEIFER FrankContributions to Conferences
2011Targeted alpha therapy with 213BiMORGENSTERN Alfred; BRUCHERTSEIFER Frank; APOSTOLIDIS ChristosArticles in Journals
2010Targeted Alpha-Radionuclide Therapy of Functionally Critical Located Gliomas with 213Bismuth-DOTA-[Thi8,Met(O2)11]-Substance P - A Pilot TrialCORDIER D.; FORRER F.; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; APOSTOLIDIS Christos; GOOD S.; MÜLLER-BRAND J.; MÄCKE H.; REUBI Jean-Claude; MERLO A.Articles in Journals
2013Targeting aberrant DNA double strand break repair in triple negative breast cancer with alpha particle emitter radiolabeled anti-EGFR antibodySONG H.; HOBBS Robert F.; SHAO Chunbo; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; DEWEESE Tl; SGOUROS G.; HEDAYATI MohammadArticles in Journals
2012Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosisESSLER M.; GAERTNER F. C.; NEFF Frauke; BLECHERT B.; SENEKOWITSCH-SCHMIDTKE R.; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; SEIDL C.Articles in Journals
2009Therapeutic efficacy of intravesical -radioimmunotherapy with Bi-213-anti-EGFR-MAb in a human bladder cancer nude mouse modelPFOST B.; SEIDL C.; AUTENRIETH M.; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; SENEKOWITSCH-SCHMIDTKE R.Contributions to Conferences
2013TiO2 nanoparticles as carries of 225Ac/213Bi in vivo generatorsLESZCZUK Edyta; PIOTROWSKA A; BILEWICZ Aleksander; MORGENSTERN Alfred; BRUCHERTSEIFER FrankContributions to Conferences
2013TiO2 nanoparticles as carries of 225Ac/213Bi in vivo generatorLESZCZUK Edyta; PIOTROWSKA A; BILEWICZ Aleksander; MORGENSTERN Alfred; BRUCHERTSEIFER FrankContributions to Conferences
2012Towards developing a universal treatment for fungal disease using radioimmunotherapy targeting common fungal antigensBRYAN R. A.; GUIMARAES A.j.; HOPCRAFT S.; JIANG Z.; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; DEL POETA M.; TOTOSANTUCCI A.; CASSONE A.; NOSANCHUK J.d., et alArticles in Journals
2012Treatment of early and established Cryptococcus neoformans infection with radiolabeled antibodies in immunocompetent miceJIANG Z.; BRYAN R. A.; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; Casadevall Arturo; DADACHOVA E.Articles in Journals
2013Treatment of experimental pancreatic cancer with 213-Bismuth-labeled chimeric antibody to single-strand DNA in combination with cisplatin and gemcitabineBRYAN R. A.; JIANG Z.; JANDL T; STRAUSS J; KOBA W; ONYEDIKA C; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; SELLERS R.; EPSTEIN A, et alContributions to Conferences
2009Treatment of Peritoneal Carcinomatosis by Targeted Delivery of the Radio-Labeled Tumor Homing Peptide 213Bi-DTPA-[F3]2 into the Nucleus of Tumor CellsDRECOLL E.; GAERTNER F. C.; MIEDERER M.; BLECHERT B.; VALLON M.; MÜLLER J.; ALKE A.; SEIDL C.; BRUCHERTSEIFER Frank; MORGENSTERN Alfred, et alArticles in Journals
2011Unprecedented Incorporation of alpha-Emitter Radioisotope 213Bi into Porphyrin Chelates with Reference to a Daughter Isotope Mediated Assistance MechanismLE GAC Stephane; NAJJARI Btissam; MOTREFF Nicolas; REMAUD-LE SAEC Patricia; FAIVRE-CHAUVET A; DIMANCHE-BOITREL M; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; LACHKAR M; BOITREL BernardArticles in Journals
Showing results 68 to 87 of 87

 

The mission of the JRC is to provide customer-driven scientific and technical support for the conception, development, implementation and monitoring of EU policies. As a service of the European Commission, the JRC functions as a reference centre of science and technology for the Union. Close to the policy-making process, it serves the common interest of the Member States, while being independent of special interests, whether private or national.
Powered by DSpace
Top